Welcome to our dedicated page for Beam Therapeutics news (Ticker: BEAM), a resource for investors and traders seeking the latest updates and insights on Beam Therapeutics stock.
Beam Therapeutics Inc. (Nasdaq: BEAM) generates frequent news as a biotechnology company developing precision genetic medicines through base editing. News about BEAM stock often centers on clinical data readouts, regulatory designations and strategic updates across its hematology and liver-targeted genetic disease franchises.
Investors following BEAM news can expect detailed updates on risto-cel (formerly BEAM-101), an investigational ex vivo base editing cell therapy for sickle cell disease with severe vaso-occlusive crises. The company regularly reports safety and efficacy data from the BEACON Phase 1/2 trial, including measures such as fetal hemoglobin induction, reductions in sickle hemoglobin, engraftment times and markers of hemolysis, as well as designations like RMAT and orphan drug status from the U.S. Food and Drug Administration.
Another major source of headlines is BEAM-302, Beam’s liver-targeting program for alpha-1 antitrypsin deficiency (AATD). Company press releases describe Phase 1/2 trial progress, dose exploration, evidence of in vivo genetic correction of a disease-causing mutation, restoration of functional alpha-1 antitrypsin and regulatory interactions, including RMAT designation, orphan drug designation and participation in the FDA’s CDRP program.
Additional BEAM news items highlight developments in BEAM-301 for glycogen storage disease type Ia, the ESCAPE platform and BEAM-103 antibody, targeted lipid nanoparticle delivery research, financial results, cash runway commentary and participation in scientific and investor conferences. Coverage may also reference Beam’s equity stake in Orbital Therapeutics and the impact of Orbital’s acquisition by Bristol Myers Squibb, as disclosed by the company.
For readers tracking BEAM, this news feed provides ongoing insight into Beam’s clinical milestones, regulatory pathways, platform evolution and corporate transactions that shape the outlook for its precision genetic medicines pipeline.
Beam Therapeutics (Nasdaq: BEAM) reported Q3 2025 results and clinical progress. Cash, cash equivalents and marketable securities were $1.1 billion as of Sept 30, 2025, with a cash runway expected into 2028. The company advanced multiple programs: expanded dosing in Part A and dose escalation in Part B of BEAM-302 (AATD), first patient dosed in Part B, BEAM-103 first healthy volunteer dosed, and BEACON (BEAM-101) data accepted for ASH presentation. BEAM-101 received RMAT designation. Q3 R&D was $109.8M, G&A $26.7M, and net loss $112.7M (‑$1.10/sh).
Beam Therapeutics (Nasdaq: BEAM) outlined 2026 strategic priorities for its liver-targeted genetic disease and hematology franchises and announced an extended operating runway. Key regulatory and clinical milestones include FDA alignment on a potential accelerated approval pathway for BEAM-302 in AATD based on 12-month biomarkers, a planned BLA submission for risto-cel as early as year-end 2026, and an expected disclosure of a new liver-targeted program in H1 2026. Beam estimates $1.25 billion in cash and marketable securities as of Dec 31, 2025, supporting operations into 2029.
Beam Therapeutics (Nasdaq: BEAM) announced that CEO John Evans will present at the 44th Annual J.P. Morgan Healthcare Conference on Tuesday, January 13, 2026 at 5:15 p.m. PT in San Francisco.
The presentation will be available via a live webcast on the company's investor website at www.beamtx.com and the webcast will be archived for 60 days after the presentation.
Beam Therapeutics (Nasdaq: BEAM) reported updated BEACON Phase 1/2 data for ristoglogene autogetemcel (risto-cel) in 31 adults and adolescents with severe sickle cell disease (data cut-off Aug 6, 2025; follow-up 0.3–20.4 months).
Key results: mean HbF >60%, mean HbS <40%, durable editing (peripheral editing 67.4% at Month 6; 72.8% at Month 12), median 1 stem cell collection cycle (median 3 total collection days), median neutrophil engraftment 17.5 days and platelet engraftment 19 days, and no investigator-reported severe VOCs post-engraftment. One patient died 4 months post-infusion; investigator attributed death likely to busulfan conditioning.
Beam Therapeutics (Nasdaq: BEAM) announced that company management will participate in a fireside chat at the 2025 Jefferies London Healthcare Conference on Wednesday, November 19, 2025 at 3:30 p.m. GMT in London.
The event will be available via a live webcast in the company's investor section at www.beamtx.com and the webcast will be archived for 60 days following the presentation.
Beam Therapeutics (Nasdaq: BEAM) will present updated safety and efficacy data from the BEACON Phase 1/2 trial of BEAM-101 for sickle cell disease at the 67th American Society of Hematology Annual Meeting, December 6-9, 2025 in Orlando.
Two presentations: a poster on Dec 6, 2025, 5:30–7:30 p.m. ET (Abstract 2532) reporting robust fetal hemoglobin induction and improvements in anemia and hemolysis; and an oral presentation on Dec 8, 2025, 5:30–5:45 p.m. ET (Abstract 1049) on CD34+ mobilization, collection, and safety comparing fixed-dose versus weight-based plerixafor dosing. Presenters: Ashish Gupta, M.D., MPH, and Haydar Frangoul, M.D.
Beam Therapeutics (Nasdaq: BEAM), a biotechnology company focused on precision genetic medicines through base editing, has announced its participation in three major investor conferences in September 2025.
The company's management will engage in fireside chats at Citi's 2025 Biopharma Back to School Conference (September 3), the 2025 Wells Fargo Healthcare Conference (September 4), and the H.C. Wainwright 27th Annual Global Investment Conference (September 8). All presentations will be available via webcast on the company's investor relations website for 60 days following each event.
Beam Therapeutics (NASDAQ:BEAM) has received Regenerative Medicine Advanced Therapy (RMAT) designation from the FDA for BEAM-101, its investigational cell therapy for sickle cell disease. The designation follows the previously granted orphan drug status and provides opportunities for accelerated development and enhanced FDA collaboration.
The company's BEACON Phase 1/2 trial has now treated 30 patients, with updated data from 17 patients showing promising results including increased fetal hemoglobin, reduced sickle hemoglobin, and improved markers of hemolysis and oxygen delivery. The treatment demonstrated rapid neutrophil and platelet engraftment, with no VOCs reported post-engraftment. Additional trial data is expected by the end of 2025.
Beam Therapeutics (NASDAQ:BEAM) reported significant progress in its Q2 2025 clinical programs and financial results. The company's lead candidate BEAM-302 for alpha-1 antitrypsin deficiency (AATD) has shown promising results with 17 patients dosed across four cohorts, demonstrating durable correction of disease-causing mutations and restored AAT physiology. All doses tested were well-tolerated with no serious adverse events.
In their hematology franchise, Beam completed dosing of 30 patients in the BEACON Phase 1/2 trial of BEAM-101 for sickle cell disease, including the first adolescent patient. The company ended Q2 2025 with a strong financial position of $1.2 billion in cash and equivalents, extending their runway into 2028. Q2 financial results showed an R&D expense of $101.8 million and a net loss of $102.3 million ($1.00 per share).
FAQ
What is the current stock price of Beam Therapeutics (BEAM)?
What is the market cap of Beam Therapeutics (BEAM)?
